(2E)-2-(cyclopropylmethylidene)-3-oxobutanenitrile

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2E)-2-(cyclopropylmethylidene)-3-oxobutanenitrile
• 化学式: C₈H₉NO
• 分子量: 135.16
• InChiKey: MXWYBJYGFNIVRV-XBXARRHUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON ET LEURS PROCÉDÉS D'UTILISATION
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018103058A1

  公开（公告）日：2018-06-14

  Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').

  公式（I'）的化合物及其使用和制备方法，以及包含公式（I'）化合物的组合物。
• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEURS UTILISATIONS
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2016090079A1

  公开（公告）日：2016-06-09

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.

  本发明提供了化合物、其药学上可接受的组合物，以及使用它们的方法。现在已经发现，本发明的化合物及其药学上可接受的组合物作为一种或多种蛋白激酶的抑制剂是有效的。这些化合物具有通式I或其药学上可接受的盐，其中环A、环B、W、Ry、R3和R4如本文所定义。
• Inhibitors of Bruton's tyrosine kinase and methods of their use
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US10689396B2

  公开（公告）日：2020-06-23

  The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′.

  本公开涉及式 I′化合物及其使用和制备方法，以及包含式 I′化合物的组合物。
• Inhibitors of Bruton's tyrosine kinase and method of their use
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US10800792B2

  公开（公告）日：2020-10-13

  The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′.

  本公开涉及式 I′化合物及其使用和制备方法，以及包含式 I′化合物的组合物。
• AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：ETERNITY BIOSCIENCE INC.

  公开号：US20170152264A1

  公开（公告）日：2017-06-01

  The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.